Study wrapper · #1038
Targeting the activin/myostatin - actrii pathway to preserve skeletal muscle mass in obesity: mechanistic insights and therapeutic perspectives.
Editor's note
A mechanistic review centered on the activin/myostatin-ActRII pathway and muscle-preserving strategies during obesity treatment. Tirzepatide and GLP-1 agonists appear mainly as the backdrop that motivates concern about lean-mass loss, with the bulk of the discussion devoted to activin-receptor blockade agents such as bimagrumab. Relevant to the ongoing conversation about muscle preservation, though the tracked peptide is peripheral to the review's focus.
Plain-language abstract
This review focuses on the activin/myostatin pathway as a way to preserve muscle during weight loss, noting that GLP-1 agonists and tirzepatide reduce fat while partly sparing muscle but can still cause meaningful lean-mass loss. The peptides are context rather than the central subject.